Skip to main content

Table 1 Baseline characteristics of included studies

From: The prognostic value of lactate dehydrogenase levels in colorectal cancer: a meta-analysis

    Sample size Age   LDH    
First author Year Country Total Colon Rectum Median Range Tumor stage Cutoff Detection method Adjuvant chemotherapy Suvival analysis Outcome report
Agrawal 2013 USA 146 NR NR NR <=50 IV 200U/L serum NR Univariate OS
Alonso-Espinaco 2014 Spanish 157 NR NR NR 28–82 mCRC NR serum FOLFOX/XELOX Univariate Multivariate OS PFS
Asmis 2011 Canada 544 NR NR NR NR NR NR serum Cetuximab-based Univariate Multivariate OS
Caputo 2014 Italy 96 88 6 NR 18–80 T2T3T4/M0 248U/L serum NO Univariate OS PFS
Cetin 2012 Turkey 168 NR NR NR NR mCRC NR serum anti-VEGF therapy Multivariate OS
Chibaudel 2011 France 535 349 177 65 29–80 mCRC NR serum Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy Univariate Multivariate OS
Diouf 2014 France 620 398 211 NR 18–80 mCRC NR serum FOLFOX4 or FOLFOX7 Univariate Multivariate OS
Formica 2013 Italy 31 26 5 69 41–83 mCRC 245U/L serum FOLFORIN + bevacizumab Multivariate PFS
Galizia 2008 Italy 65 53 12 NR 28–84 IV with liver metastasis 450U/L serum fluorouracil, folinic and acid, and oxaliplatin/irinotecan Multivariate OS
Giessen 2013 German 215 136 79 61.8 32–78 mCRC/liver metastas 250U/L serum FUFURI or mIROX Multivariate OS
Giessen 2014 Italy 249 0 249 64.6 30.6–90.7 I-III 171 serum Chemotherapy/Radiotherapy/Concomitant chemoradiotherapy Univariate OS
Hannisdal 1994 Norway 100 0 100 69 33–87 Local regional relapse ± metastasis 500 serum chemoradiotherapy Multivariate OS
He 2013 China 239 171 68 57 18–83 mCRC 245U/L serum Folfox/Xelox/Folfiri/Xeliri Multivariate OS
Koukourakis 2006 UK 128 78 50 67 41–88 Dukes B,C,D NR IHC NO Univariate OS
Koukourakis 2011 Greece 179 NR NR NR 28–83 mCRC NR serum IHC FOLFOX4 + vatalanib/placebo Univariate Multivariate OS
Lin 2006 USA 66 NR NR 62 30–86 mCRC 618 serum XCEL ± Radiation Univariate OS
Lin 2005 China 45 34 11 32 18–39 Dukes B,C,D 230 serum 5-FU based chemotherapy Multivariate OS
Machida 2008 Japan 103 66 37 62 29–80 mCRC 300 serum LV-modulated 5-FU/irinotecan + 5-FU Univariate OS
Maurel 2007 Spain 120 NR NR 66 33–82 mCRC 450 serum 5-FU + oxaliplatin/irinotecan Multivariate OS
Mekenkam 2012 Netherland 803 538 260 63 27–84 Advanced stage (curative surgery) NR serum capecitabine, irinotecan, oxaliplatin: Sequential VS Combination Multivariate OS